% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Jost:875374,
author = {Jost, Stefanie Theresa and Sauerbier, Anna and
Visser-Vandewalle, Veerle and Ashkan, Keyoumars and
Silverdale, Monty and Evans, Julian and Loehrer, Philipp A
and Rizos, Alexandra and Petry-Schmelzer, Jan Niklas and
Reker, Paul and Fink, Gereon Rudolf and Franklin, Jeremy and
Samuel, Michael and Schnitzler, Alfons and Barbe, Michael
Thomas and Antonini, Angelo and Martinez-Martin, Pablo and
Timmermann, Lars and Ray-Chaudhuri, K. and Dafsari, Haidar
S},
title = {{A} prospective, controlled study of non-motor effects of
subthalamic stimulation in {P}arkinson’s disease: results
at the 36-month follow-up},
journal = {Journal of neurology, neurosurgery, and psychiatry},
volume = {91},
number = {7},
issn = {1468-330X},
address = {London},
publisher = {BMJ Publishing Group},
reportid = {FZJ-2020-01988},
pages = {687-694},
year = {2020},
abstract = {Objective To examine 36-month effects of bilateral
subthalamic nucleus deep brain stimulation (STN-DBS) on
non-motor symptoms (NMS) compared with standard-of-care
medical treatment (MED) in Parkinson’s disease
(PD).Methods Here we report the 36-month follow-up of a
prospective, observational, controlled, international
multicentre study of the NILS cohort. Assessments included
NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for
Outcomes in PD (SCOPA)-motor examination, -activities of
daily living, and -complications, and levodopa equivalent
daily dose (LEDD). Propensity score matching resulted in a
pseudo-randomised sub-cohort balancing baseline demographic
and clinical characteristics between the STN-DBS and MED
groups. Within-group longitudinal outcome changes were
analysed using Wilcoxon signed-rank and between-group
differences of change scores with Mann-Whitney U test.
Strength of clinical responses was quantified with Cohen’s
effect size. In addition, bivariate correlations of change
scores were explored.Results Propensity score matching
applied on the cohort of 151 patients (STN-DBS n=67, MED
n=84) resulted in a well-balanced sub-cohort including 38
patients per group. After 36 months, STN-DBS significantly
improved NMSS, PDQ-8, SCOPA-motor examination and
-complications and reduced LEDD. Significant between-group
differences, all favouring STN-DBS, were found for NMSS,
SCOPA-motor complications, LEDD (large effects), motor
examination and PDQ-8 (moderate effects). Furthermore,
significant differences were found for the sleep/fatigue,
urinary (large effects) and miscellaneous NMSS domains
(moderate effects). NMSS total and PDQ-8 change scores
correlated significantly.Conclusions This study provides
Class IIb evidence for beneficial effects of STN-DBS on NMS
at 36-month follow-up which also correlated with quality of
life improvements. This highlights the importance of NMS for
DBS outcomes assessments.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32371534},
UT = {WOS:000545962100005},
doi = {10.1136/jnnp-2019-322614},
url = {https://juser.fz-juelich.de/record/875374},
}